Assessment Status |
Awaiting response from Applicant |
HTA ID |
22050 |
Drug |
Trastuzumab deruxtecan |
Brand |
Enhertu® |
Indication |
As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. |
Rapid review commissioned |
11/07/2022 |
Rapid review completed |
27/07/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
31/08/2022 |
Pre-submission consultation with Applicant |
25/10/2022 |
Full submission received from Applicant |
09/03/2023 |
Preliminary review sent to Applicant |
15/09/2023 |